[{"id":"cc0ff819-00f0-4f9d-9b06-d419790f5cbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04797468","created_at":"2022-10-26T18:06:23.272Z","updated_at":"2024-07-02T16:35:57.547Z","phase":"Phase 1","brief_title":"A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor","source_id_and_acronym":"NCT04797468","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" CD68","pipe":"","alterations":" ","tags":["CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLX23"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/18/2022","start_date":" 07/18/2022","primary_txt":" Primary completion: 01/13/2023","primary_completion_date":" 01/13/2023","study_txt":" Completion: 01/13/2023","study_completion_date":" 01/13/2023","last_update_posted":"2023-01-16"}]